Research
Hormonal
Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.
If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.
StrongSupportsVERY_HIGH confidence
Major kidney disease events occurred less frequently in the semaglutide group... resulting in a 24% lower relative risk of the primary outcome in the semaglutide group (HR 0.76; 95% CI 0.66 to 0.88; p = 0.0003)... Fewer MACE events occurred in the semaglutide group... an 18% difference (HR 0.82 (95% CI 0.68 to 0.98; p = 0.029)
Why this rating
Based on a large, randomized, placebo-controlled trial (FLOW) with clear statistical significance.
Source
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell et al. · Cardiovascular Diabetology · 2025
narrative_reviewCited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →